LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | Barasertib | 1.11 | uM | LJP5 | 3 | D09 | 72 | hr | 1334 | 1645 | 4117 | 0.3995 | 0.1373 |
BT-20 | Barasertib | 3.33 | uM | LJP5 | 1 | D08 | 72 | hr | 1334 | 1118 | 3930 | 0.2844 | -0.1075 |
BT-20 | Barasertib | 3.33 | uM | LJP5 | 2 | D08 | 72 | hr | 1334 | 1243 | 4051 | 0.3068 | -0.0435 |
BT-20 | Barasertib | 3.33 | uM | LJP5 | 3 | D08 | 72 | hr | 1334 | 1357 | 4117 | 0.3296 | 0.0103 |
BT-20 | Barasertib | 10 | uM | LJP5 | 1 | D07 | 72 | hr | 1334 | 941 | 3930 | 0.2394 | -0.2009 |
BT-20 | Barasertib | 10 | uM | LJP5 | 2 | D07 | 72 | hr | 1334 | 984 | 4051 | 0.2429 | -0.1733 |
BT-20 | Barasertib | 10 | uM | LJP5 | 3 | D07 | 72 | hr | 1334 | 1074 | 4117 | 0.2608 | -0.1251 |
BT-20 | Vemurafenib | 0.04 | uM | LJP5 | 1 | C18 | 72 | hr | 1334 | 3410 | 3930 | 0.8675 | 0.8257 |
BT-20 | Vemurafenib | 0.04 | uM | LJP5 | 2 | C18 | 72 | hr | 1334 | 3913 | 4051 | 0.9659 | 0.9572 |
BT-20 | Vemurafenib | 0.04 | uM | LJP5 | 3 | C18 | 72 | hr | 1334 | 4169 | 4117 | 1.0125 | 1.0153 |
BT-20 | Vemurafenib | 0.12 | uM | LJP5 | 1 | C17 | 72 | hr | 1334 | 3523 | 3930 | 0.8963 | 0.8643 |
BT-20 | Vemurafenib | 0.12 | uM | LJP5 | 2 | C17 | 72 | hr | 1334 | 3809 | 4051 | 0.9403 | 0.9245 |
BT-20 | Vemurafenib | 0.12 | uM | LJP5 | 3 | C17 | 72 | hr | 1334 | 4094 | 4117 | 0.9943 | 0.9929 |
BT-20 | Vemurafenib | 0.37 | uM | LJP5 | 1 | C16 | 72 | hr | 1334 | 3598 | 3930 | 0.9153 | 0.8896 |
BT-20 | Vemurafenib | 0.37 | uM | LJP5 | 2 | C16 | 72 | hr | 1334 | 4081 | 4051 | 1.0074 | 1.0092 |
BT-20 | Vemurafenib | 0.37 | uM | LJP5 | 3 | C16 | 72 | hr | 1334 | 4244 | 4117 | 1.0307 | 1.0375 |
BT-20 | Vemurafenib | 1.11 | uM | LJP5 | 1 | C15 | 72 | hr | 1334 | 3617 | 3930 | 0.9202 | 0.8960 |
BT-20 | Vemurafenib | 1.11 | uM | LJP5 | 2 | C15 | 72 | hr | 1334 | 4227 | 4051 | 1.0434 | 1.0538 |
BT-20 | Vemurafenib | 1.11 | uM | LJP5 | 3 | C15 | 72 | hr | 1334 | 4007 | 4117 | 0.9731 | 0.9668 |
BT-20 | Vemurafenib | 3.33 | uM | LJP5 | 1 | C14 | 72 | hr | 1334 | 3180 | 3930 | 0.8090 | 0.7457 |
BT-20 | Vemurafenib | 3.33 | uM | LJP5 | 2 | C14 | 72 | hr | 1334 | 3623 | 4051 | 0.8943 | 0.8653 |
BT-20 | Vemurafenib | 3.33 | uM | LJP5 | 3 | C14 | 72 | hr | 1334 | 3984 | 4117 | 0.9675 | 0.9598 |
BT-20 | Vemurafenib | 10 | uM | LJP5 | 1 | C13 | 72 | hr | 1334 | 2633 | 3930 | 0.6698 | 0.5465 |
BT-20 | Vemurafenib | 10 | uM | LJP5 | 2 | C13 | 72 | hr | 1334 | 2654 | 4051 | 0.6551 | 0.5359 |
BT-20 | Vemurafenib | 10 | uM | LJP5 | 3 | C13 | 72 | hr | 1334 | 3008 | 4117 | 0.7305 | 0.6486 |